150 related articles for article (PubMed ID: 6381432)
21. The potential superiority of bromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer.
Lawrence TS; Davis MA; Maybaum J; Mukhopadhyay SK; Stetson PL; Normolle DP; McKeever PE; Ensminger WD
Cancer Res; 1992 Jul; 52(13):3698-704. PubMed ID: 1617642
[TBL] [Abstract][Full Text] [Related]
22. 1977 Henry H. Janeway lecture: fundamental mechanisms in combined modality therapy of cancer.
Kaplan HS
AJR Am J Roentgenol; 1977 Sep; 129(3):383-93. PubMed ID: 409189
[No Abstract] [Full Text] [Related]
23. Modification of radiotherapy by radiosensitizers and cancer chemotherapy agents. I. Radiosensitizers.
Coleman CN
Semin Oncol; 1989 Jun; 16(3):169-75. PubMed ID: 2658080
[No Abstract] [Full Text] [Related]
24. [Radiation sensitizers: with special reference to hypoxic cell sensitizers].
Onoyama Y; Nakajima T; Tanaka M
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):894-903. PubMed ID: 3963856
[TBL] [Abstract][Full Text] [Related]
25. The experimental and clinical rationale for the use of S-phase-specific radiosensitizers to overcome tumor cell repopulation.
McGinn CJ; Kinsella TJ
Semin Oncol; 1992 Aug; 19(4 Suppl 11):21-8. PubMed ID: 1509278
[TBL] [Abstract][Full Text] [Related]
26. Sensitizers of photoradiation and ionizing radiation in the management of head and neck cancer.
Lebovics RS; DeLaney TF
Med Clin North Am; 1993 May; 77(3):583-96. PubMed ID: 8492611
[TBL] [Abstract][Full Text] [Related]
27. Photon activation therapy.
Fairchild RG; Bond VP
Strahlentherapie; 1984 Dec; 160(12):758-63. PubMed ID: 6515666
[TBL] [Abstract][Full Text] [Related]
28. BUdR radiosensitization in anaplastic astrocytoma.
Yung WK
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1105-6. PubMed ID: 10613300
[No Abstract] [Full Text] [Related]
29. Experimental and clinical studies of radiosensitizers in brain tumors, with special reference to BUdR-antimetabolite continuous regional infusion-radiation therapy (BAR therapy).
Sano K; Sato F; Hoshino T; Nagai M
Neurol Med Chir (Tokyo); 1965; 7():51-72. PubMed ID: 4162242
[No Abstract] [Full Text] [Related]
30. Synthetic, implantable polymers for IUdR radiosensitization of experimental human malignant glioma.
Yuan X; Dillehay LE; Williams JR; Williams JA
Cancer Biother Radiopharm; 1999 Jun; 14(3):187-202. PubMed ID: 10850303
[TBL] [Abstract][Full Text] [Related]
31. DNA topoisomerase I-targeting drugs as radiation sensitizers.
Chen AY; Choy H; Rothenberg ML
Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):39-46. PubMed ID: 10550825
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of atomic inner shell ionization (ISI) and Auger cascade for radiosensitization using IUdR, BUdR, platinum salts, or gadolinium porphyrin compounds.
Pignol JP; Rakovitch E; Beachey D; Le Sech C
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):1082-91. PubMed ID: 12605988
[TBL] [Abstract][Full Text] [Related]
33. Radiosensitizers: rationale and potential.
Brown JM
Cancer Treat Rep; 1981; 65 Suppl 2():95-102. PubMed ID: 7346152
[TBL] [Abstract][Full Text] [Related]
34. The interaction between two radiosensitizers: 5-iododeoxyuridine and caffeine.
Seo Y; Yan T; Schupp JE; Yamane K; Radivoyevitch T; Kinsella TJ
Cancer Res; 2006 Jan; 66(1):490-8. PubMed ID: 16397265
[TBL] [Abstract][Full Text] [Related]
35. A phase I study of intravenous iododeoxyuridine as a clinical radiosensitizer.
Kinsella TJ; Russo A; Mitchell JB; Collins JM; Rowland J; Wright D; Glatstein E
Int J Radiat Oncol Biol Phys; 1985 Nov; 11(11):1941-6. PubMed ID: 2997090
[TBL] [Abstract][Full Text] [Related]
36. Antimetabolite radiosensitizers.
Shewach DS; Lawrence TS
J Clin Oncol; 2007 Sep; 25(26):4043-50. PubMed ID: 17827452
[TBL] [Abstract][Full Text] [Related]
37. Radiopharmaceuticals (Strontium 89) and radiosensitizers (idoxuridine).
Otto SE
J Intraven Nurs; 1998; 21(6):335-7. PubMed ID: 10392098
[TBL] [Abstract][Full Text] [Related]
38. Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study.
Schulz CA; Mehta MP; Badie B; McGinn CJ; Robins HI; Hayes L; Chappell R; Volkman J; Binger K; Arzoomanian R; Simon K; Alberti D; Feierabend C; Tutsch KD; Kunugi KA; Wilding G; Kinsella TJ
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1107-15. PubMed ID: 15234045
[TBL] [Abstract][Full Text] [Related]
39. The effect of single versus double-strand substitution on halogenated pyrimidine-induced radiosensitization and DNA strand breakage in human tumor cells.
Lawrence TS; Davis MA; Maybaum J; Stetson PL; Ensminger WD
Radiat Res; 1990 Aug; 123(2):192-8. PubMed ID: 2389005
[TBL] [Abstract][Full Text] [Related]
40. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine.
Berry SE; Davis TW; Schupp JE; Hwang HS; de Wind N; Kinsella TJ
Cancer Res; 2000 Oct; 60(20):5773-80. PubMed ID: 11059773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
